Moreover, it highly likely that other bioactive molecules (such as tau) may potentiate or attenuate Aβ activity, and that variation in the levels of such molecules could underlie differences in the Aβ-dependent bioactivity of extracts from different AD brains. This evidence concerns the gene MAPT and Alzheimer disease.